Zilly W, Breimer D D, Richter E
Eur J Clin Pharmacol. 1977 Apr 20;11(4):287-93. doi: 10.1007/BF00607679.
Eleven patients with hepatic cirrhosis or cholestasis were treated with rifampicin for 7 to 132 days. Ten patients received hexobarbital (7.32 mg/kg) and five received tolbutamide (20 mg/kg) by i.v. infusion prior to and after rifampicin treatment; plasma concentrations of the two test compounds were determined during and after infusion. The average elimination half-life of hexobarbital had decreased from 624 to 262 min and that of tolbutamide from 292 to 160 min following rifampicin treatment. It was calculated that the metabolic clearance of hexobarbital had increased more than two-fold and that of tolbutamide almost two-fold. The results suggests that rifampicin is able to stimulate hepatic drug metabolism in patients with liver disease. It was apparent in general that the induction did not lead to improvement of hepatocellular function during disease as judged by laboratory findings.
11例肝硬化或胆汁淤积患者接受利福平治疗7至132天。10例患者在利福平治疗前后通过静脉输注接受己巴比妥（7.32mg/kg），5例接受甲苯磺丁脲（20mg/kg）；在输注期间和之后测定两种受试化合物的血浆浓度。利福平治疗后，己巴比妥的平均消除半衰期从624分钟降至262分钟，甲苯磺丁脲的平均消除半衰期从292分钟降至160分钟。据计算，己巴比妥的代谢清除率增加了两倍多，甲苯磺丁脲的代谢清除率几乎增加了两倍。结果表明，利福平能够刺激肝病患者的肝脏药物代谢。从实验室检查结果判断，一般明显的是，这种诱导在疾病期间并未导致肝细胞功能的改善。
